Chengdu Eyes China’s Silicon Valley, Not Just “Panda City”

CHENGDU, China, Sept. 27, 2016 /Kyodo JBN/ — Located in the southwestern hinterland of China, Chengdu, the capital of Sichuan province, is pushing to become China’s Silicon Valley, not just a place known for giant panda bears and spicy cuisine. The megalopolis is assisting start-up businesses, developing a huge “state-level new area” ー “Tianfu New Area” ー encompassing industry, high-tech... [Read More...]

HOYA Launches Yuniku, a Global First in Vision-centric, 3D Tailored Eyewear

PR65843 UITHOORN, the Netherlands, Sept 23, 2016 /PRNewswire=KYODO JBN/ — HOYA Vision Care Company, a key player in the global market for ophthalmic lenses, is proud to announce a global premiere: Yuniku, the world’s first 3D tailored eyewear that is designed entirely around the optimal vision of the wearer. Yuniku is the result of a highly successful partnership with Materialise, leading provider... [Read More...]

Merck and the Royal Health Awareness Society Partner to Advance Women’s Health in Jordan

PR65854 DARMSTADT, Germany, Sept. 23 /PRNewswire=KYODO JBN/ — – New partnership under Healthy Women, Healthy Economies initiative facilitates women to overcome health barriers to economic participation Merck, a leading science and technology company, today announced its partnership with the Royal Health Awareness Society (RHAS) of Jordan to advance health awareness and education particularly on... [Read More...]

Steven Chang Decodes Digital China with Tech Intelligence At ad:tech tokyo

PR65825 TOKYO, Sept. 21, 2016 /PRNewswire=KYODO JBN/ — Steven Chang Decodes Digital China with Tech Intelligence At ad:tech tokyo TOKYO, Sept. 21, 2016 /PRNewswire/ — Speaking on September 20th at ad:tech tokyo 2016, one of Asia’s largest digital marketing conferences, Steven Chang, Corporate Vice President of Tencent, addressed the topic “Decoding Digital China with Tech Intelligence.”... [Read More...]

Semaglutide Reduced Major Cardiovascular Events by 26% in Adults With Type 2 Diabetes at High Cardiovascular Risk

PR65768 MUNICH, Sep. 16 /PRNewswire=KYODO JBN/– HOLD UNTIL 16/09/2016 16:31 SYDNEY TIME This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint... [Read More...]

Toujeo(R) Demonstrates a More Stable Profile and Lower Within-day Variability Compared to Insulin Degludec

PR65766 PARIS, Sep. 15, 2016 /PRNewswire=KYODO JBN/ — Further comparative data expected from ongoing head-to-head clinical trial Sanofi [http://www.sanofi.com ] announced today the key results of a new pharmacokinetic / pharmacodynamic (PK/PD) study in people with type 1 diabetes comparing Toujeo(R) (insulin glargine 300 Units/mL) to insulin degludec U100. The study demonstrated a more stable PK/PD... [Read More...]

Volvo Cars Reveals Its Adventurous Side With New V90 Cross Country

PR65764 GOTHENBURG, Sweden, Sept. 16, 2016 /PRNewswire=KYODO JBN/ — Volvo Cars, the premium carmaker, has unveiled the eagerly awaited V90 Cross Country, completing its 90 Series line-up. Since the introduction of the first Cross Country almost 20 years ago, Volvo Cars has become synonymous with the rugged all-road, all-weather product category, with a growing stable of Cross Country models. To view... [Read More...]

Victoza(R) lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk

PR65765 MUNICH, Sept. 16 /PRNewswire=KYODO JBN/ — This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza(R) treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults with... [Read More...]

Saxenda(R) Provides Consistent Weight Loss and Improvements in Blood Glucose Control Across BMI Categories After Three Years of Treatment

PR65748 MUNICH, Sep. 14 / PRNewswire=KYODO JBN / — This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial show that people treated with Saxenda(R) (liraglutide 3 mg) experienced consistent... [Read More...]

Adults with Type 2 Diabetes Treated with Xultophy(R) (IDegLira) were up to 4.5 Times More Likely to Reach Glycaemic Targets Without Hypoglycaemia and Weight Gain vs Up-titration with Insulin Glargine U100

PR65684 Adults with Type 2 Diabetes Treated with Xultophy(R) (IDegLira) were up to 4.5 Times More Likely to Reach Glycaemic Targets Without Hypoglycaemia and Weight Gain vs Up-titration with Insulin Glargine U100 MUNICH, Germany, Sept. 13, 2016 /PRNewswire=KYODO JBN/– This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk... [Read More...]

Next Page »